A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: an Asian experience.

نویسندگان

  • Sirirat Anutrakulchai
  • Thanachai Panaput
  • Jeerapat Wongchinsri
  • Somchai Chaishayanon
  • Bancha Satirapoj
  • Opas Traitanon
  • Warabhorn Pima
  • Chutima Rukrung
  • Bandit Thinkhamrop
  • Yingyos Avihingsanon
چکیده

OBJECTIVE The optimal treatment of relapse or resistant lupus nephritis (LN) is still unclear. Mycophenolate might be an alternative therapy to avoid toxicities of cyclophosphamide (CYC). This study was aimed to compare enteric-coated mycophenolate sodium (EC-MPS) versus intravenous CYC as an induction therapy. METHODS The study was a 12-month period of multicentre, open-labelled randomised controlled trial. Fifty-nine patients who had relapsed (36%) or who were resistant to previous CYC treatment (64%) and all who were biopsy-proven class III/IV, were randomised into CYC (n=32) and EC-MPS groups (n=27). The CYC group received intravenous CYC 0.5-1 g/m(2) monthly and the EC-MPS group was treated with EC-MPS 1440 mg/day for first 6 months. After induction therapy, both groups received EC-MPS 720 mg/day until the end of study at 12 months. RESULTS The study was prematurely terminated due to high rate of serious adverse events in CYC arm. Death and serious infections were observed more in the CYC group (15.6% in CYC and 3.5% in EC-MPS; p=0.04). The early discontinuation rates, mainly from serious infections, were significantly higher in CYC group (percentage differences of 16.9; 95% CI 1.3 to 32.4). At the 12th month, both arms were comparable in terms of complete and partial remission rates (68% CYC and 71% EC-MPS) and times to remission (96 days CYC and 97 days EC-MPS). Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment) were 46.9% and 37% in CYC and EC-MPS (risk difference=9.84; p=0.44). CONCLUSIONS EC-MPS may have comparable efficacy, but was better tolerated than CYC. EC-MPS should be an alternative choice of treatment for difficult-to-treat LN, particularly in CYC-experienced LN patients. Due to an early termination of the study, further clinical implementation could be cautiously used. TRIAL REGISTRATION NUMBER Clinicaltrials.gov ID#NCT01015456.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis.

Mycophenolic acid, in combination with glucocorticoids, has been shown in a series of trials to be safe and effective for treatment of lupus nephritis. Regimens that permit glucocorticoid dose reduction without loss of efficacy would be advantageous. MyLupus was a 24-week, multicentre, open-label, study in patients with active proliferative lupus nephritis treated with enteric-coated mycophenol...

متن کامل

A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial

INTRODUCTION Mycophenolate sodium, an enteric-coated tablet (EC-MPS), is as effective and safe as mycophenolate mofetil (MMF) in preventing transplant rejection. EC-MPS and MMF improve the outcome of severe lupus nephritis (LN) and have fewer side effects than pulsed intravenous cyclophosphamide. Blood concentrations of mycophenolic acid (MPA), the active metabolite of EC-MPS, vary between part...

متن کامل

نتایج درمان نفریت لوپوسی پرولیفراتیو مقاوم به درمان با سیکلوسپورین A

Background & Aims: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by various autoantibodies formation and immune complex deposition in various organs. Lupus nephritis is a common and severe manifestation of SLE that can lead to end stage renal disease and death. The aim of this study was to evaluate the long-term efficacy of cyclosporine A in the treat...

متن کامل

Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study

INTRODUCTION While the role of mycophenolate mofetil (MMF) in the management of lupus nephritis has been increasingly recognized, limited information is available regarding its efficacy and safety as a long-term maintenance treatment. The aim of the present study was to evaluate the efficacy and safety profile of MMF as maintenance therapy for proliferative lupus nephritis. METHODS Thirty-thr...

متن کامل

درمان کودک مبتلا به نفریت هنوخ شوئن لاینه‌ای با مایکوفنولیت مافتیل cellcept))

 Received: 18 Aug, 2008 Accepted: 14 Feb, 2009  Abstract  Renal involvement is one of the most serious sequela of Henoch-Schönlein purpura. The presence of proteinuria (nephritic range) and hematuria is also associated with progression to renal insufficiency. In fifty percent of patients who display a combination of nephritis-nephrotic symptoms, end-stage disease develops. Pharmacologic treatme...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Lupus science & medicine

دوره 3 1  شماره 

صفحات  -

تاریخ انتشار 2016